Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide

Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE), after the completion of large-scale randomized comparative clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales: De Caterina, Raffaele, Ageno, Walter, Boriani, Giuseppe, Colonna, Paolo, Ghirarduzzi, Angelo, Patti, Giuseppe, Rossini, Roberta, Rubboli, Andrea, Schinco, Piercarla, Agnelli, Giancarlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350200/
https://www.ncbi.nlm.nih.gov/pubmed/28194578
http://dx.doi.org/10.1007/s12325-017-0488-9
_version_ 1782514613643902976
author De Caterina, Raffaele
Ageno, Walter
Boriani, Giuseppe
Colonna, Paolo
Ghirarduzzi, Angelo
Patti, Giuseppe
Rossini, Roberta
Rubboli, Andrea
Schinco, Piercarla
Agnelli, Giancarlo
author_facet De Caterina, Raffaele
Ageno, Walter
Boriani, Giuseppe
Colonna, Paolo
Ghirarduzzi, Angelo
Patti, Giuseppe
Rossini, Roberta
Rubboli, Andrea
Schinco, Piercarla
Agnelli, Giancarlo
author_sort De Caterina, Raffaele
collection PubMed
description Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE), after the completion of large-scale randomized comparative clinical trials with the vitamin K antagonist warfarin. Edoxaban has some peculiar pharmacological properties and outcome data. Here a group of experts in AF and VTE answers a set of questions on its practical use, trying to define the profile of patients that would be most appropriate for its use.
format Online
Article
Text
id pubmed-5350200
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-53502002017-03-27 Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide De Caterina, Raffaele Ageno, Walter Boriani, Giuseppe Colonna, Paolo Ghirarduzzi, Angelo Patti, Giuseppe Rossini, Roberta Rubboli, Andrea Schinco, Piercarla Agnelli, Giancarlo Adv Ther Review Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE), after the completion of large-scale randomized comparative clinical trials with the vitamin K antagonist warfarin. Edoxaban has some peculiar pharmacological properties and outcome data. Here a group of experts in AF and VTE answers a set of questions on its practical use, trying to define the profile of patients that would be most appropriate for its use. Springer Healthcare 2017-02-13 2017 /pmc/articles/PMC5350200/ /pubmed/28194578 http://dx.doi.org/10.1007/s12325-017-0488-9 Text en © The Author(s) 2017 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
De Caterina, Raffaele
Ageno, Walter
Boriani, Giuseppe
Colonna, Paolo
Ghirarduzzi, Angelo
Patti, Giuseppe
Rossini, Roberta
Rubboli, Andrea
Schinco, Piercarla
Agnelli, Giancarlo
Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide
title Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide
title_full Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide
title_fullStr Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide
title_full_unstemmed Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide
title_short Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide
title_sort edoxaban in atrial fibrillation and venous thromboembolism—ten key questions and answers: a practical guide
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350200/
https://www.ncbi.nlm.nih.gov/pubmed/28194578
http://dx.doi.org/10.1007/s12325-017-0488-9
work_keys_str_mv AT decaterinaraffaele edoxabaninatrialfibrillationandvenousthromboembolismtenkeyquestionsandanswersapracticalguide
AT agenowalter edoxabaninatrialfibrillationandvenousthromboembolismtenkeyquestionsandanswersapracticalguide
AT borianigiuseppe edoxabaninatrialfibrillationandvenousthromboembolismtenkeyquestionsandanswersapracticalguide
AT colonnapaolo edoxabaninatrialfibrillationandvenousthromboembolismtenkeyquestionsandanswersapracticalguide
AT ghirarduzziangelo edoxabaninatrialfibrillationandvenousthromboembolismtenkeyquestionsandanswersapracticalguide
AT pattigiuseppe edoxabaninatrialfibrillationandvenousthromboembolismtenkeyquestionsandanswersapracticalguide
AT rossiniroberta edoxabaninatrialfibrillationandvenousthromboembolismtenkeyquestionsandanswersapracticalguide
AT rubboliandrea edoxabaninatrialfibrillationandvenousthromboembolismtenkeyquestionsandanswersapracticalguide
AT schincopiercarla edoxabaninatrialfibrillationandvenousthromboembolismtenkeyquestionsandanswersapracticalguide
AT agnelligiancarlo edoxabaninatrialfibrillationandvenousthromboembolismtenkeyquestionsandanswersapracticalguide

Ejemplares similares